Skip to main content

Phase 1/2 study with an open-label dose escalation phase followed by a randomized, double-blind phase of SLN124 in patients with Polycythemia Vera

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Silence Therapeutics PLC

Start Date

March 26, 2024

End Date

March 14, 2029
 

Administered By

Duke Cancer Institute

Awarded By

Silence Therapeutics PLC

Start Date

March 26, 2024

End Date

March 14, 2029